Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Ligand Pharmaceuticals stock price, quote, forecast and news

LGND
US53220K5048
A1C9RN

Price

103.09
Today +/-
+0.78
Today %
+0.84 %
P

Ligand Pharmaceuticals stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Ligand Pharmaceuticals stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Ligand Pharmaceuticals stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Ligand Pharmaceuticals stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Ligand Pharmaceuticals's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Ligand Pharmaceuticals Stock Price History

DateLigand Pharmaceuticals Price
9/11/2024103.09 undefined
9/10/2024102.23 undefined
9/9/2024102.78 undefined
9/6/2024101.14 undefined
9/5/2024103.15 undefined
9/4/2024102.56 undefined
9/3/2024100.95 undefined
8/30/2024105.80 undefined
8/29/2024105.86 undefined
8/28/2024106.54 undefined
8/27/2024106.33 undefined
8/26/2024105.20 undefined
8/23/2024103.82 undefined
8/22/2024103.62 undefined
8/21/2024106.08 undefined
8/20/2024104.34 undefined
8/19/2024103.59 undefined
8/16/2024102.21 undefined
8/15/2024103.13 undefined

Ligand Pharmaceuticals Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Ligand Pharmaceuticals, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Ligand Pharmaceuticals from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Ligand Pharmaceuticals’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Ligand Pharmaceuticals. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Ligand Pharmaceuticals’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Ligand Pharmaceuticals’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Ligand Pharmaceuticals’s growth potential.

Ligand Pharmaceuticals Revenue, EBIT and net profit per share

DateLigand Pharmaceuticals RevenueLigand Pharmaceuticals EBITLigand Pharmaceuticals Net Income
2030e490.57 M undefined183.96 M undefined0 undefined
2029e361.64 M undefined143.08 M undefined0 undefined
2028e296.42 M undefined103.75 M undefined0 undefined
2027e240.99 M undefined78.32 M undefined0 undefined
2026e225.99 M undefined116.79 M undefined137.34 M undefined
2025e185.48 M undefined88.5 M undefined116.44 M undefined
2024e156.78 M undefined24.24 M undefined100.5 M undefined
2023131.31 M undefined9.82 M undefined52.15 M undefined
2022196.2 M undefined3 M undefined-33.4 M undefined
2021277.1 M undefined78.9 M undefined57.1 M undefined
2020186.4 M undefined8.7 M undefined-3 M undefined
2019120.3 M undefined-5.7 M undefined629.3 M undefined
2018251.5 M undefined163.7 M undefined143.3 M undefined
2017141.1 M undefined68.1 M undefined12.6 M undefined
2016109 M undefined44.9 M undefined-1.6 M undefined
201571.9 M undefined28.3 M undefined229.8 M undefined
201464.5 M undefined20.7 M undefined12 M undefined
201349 M undefined15.9 M undefined11.4 M undefined
201231.4 M undefined1.2 M undefined-500,000 undefined
201130 M undefined1.9 M undefined9.7 M undefined
201023.5 M undefined-9.7 M undefined-10.4 M undefined
200938.9 M undefined5.7 M undefined-1.9 M undefined
200827.3 M undefined-25.3 M undefined-98.1 M undefined
200712.9 M undefined-60.2 M undefined281.7 M undefined
20064 M undefined-78.1 M undefined-31.7 M undefined
200510.2 M undefined-43.6 M undefined-36.4 M undefined
2004112.1 M undefined-15.4 M undefined-45.2 M undefined

Ligand Pharmaceuticals Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
19871988198919901991199219931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024e2025e2026e2027e2028e2029e2030e
0000151613243651174048767181112104122738233031496471109141251120186277196131156185225240296361490
-----400.00220.00-18.7584.6250.0041.67-66.67135.2920.0058.33-6.5814.0838.27-91.07-60.00200.00125.0040.74-39.4730.433.3358.0630.6110.9453.5229.3678.01-52.1955.0048.92-29.24-33.1619.0818.5921.626.6723.3321.9635.73
----------100.00100.0075.0081.2581.5880.2866.6783.04----100.00100.0083.3387.1087.7685.9492.9694.5095.7497.6190.0083.8777.6272.9691.60-------
000000000051173039625754930000382325274355661031352451081562151431200000000
0-2-3-4-6-12-14-20-25-32-30-69-56-45-23-43-74-15-43-78-60-255-9111520284468163-587839248811678103143183
-----600.00-240.00-87.50-153.85-104.17-88.89-58.82-405.88-140.00-93.75-30.26-60.56-91.36-13.39-430.00-1,950.00-500.00-92.5913.16-39.133.333.2330.6131.2539.4440.3748.2364.94-4.174.3028.161.536.8715.3847.5751.5632.5034.8039.6137.35
0-2-2-4-6-14-19-27-64-37-100-117-74-72-43-52-96-45-36-31281-98-1-10901112229-112143629-357-33521001161370000
---100.0050.00133.3335.7142.11137.04-42.19170.2717.00-36.75-2.70-40.2820.9384.62-53.13-20.00-13.89-1,006.45-134.88-98.98900.00-190.00--9.091,808.33-100.44-1,300.001,091.67339.86-100.48-2,000.00-157.89-257.5892.3116.0018.10----
0.20.20.30.30.41.72.72.944.85.56.77.99.39.911.511.812.312.313.416.415.918.919.619.719.920.721.421.220.823.524.119.816.217.216.917.760000000
--------------------------------------------
Details

Keystats

ⓘ

Revenue and Growth

The Ligand Pharmaceuticals Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Ligand Pharmaceuticals is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (B)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (B)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (B)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (B)
1990199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
                                                                   
000.060.040.040.070.080.080.070.050.020.040.060.10.110.090.170.090.080.050.020.020.010.020.170.20.140.20.771.070.410.340.210.17
002.12.61.22.33.1001.72.89.812.218.930.82111.5000.616.14.62.212.66.214.725.655.930.456.885.530.432.92
000000000010000004.114.312.110.312.76.34.34.51.54.83.54.48.511.32.36.14.66.4
000000006.25.75.73.84.88.57.29.33.900001.31.71.40.31.61.94.47.17.326.527.313.323.97
0.10.40.61.22.10.61.70.91.92.12.52.37.316.317.715.844.21.31.140.61.40.80.84.71.91.9125.24.73.84.73.43.84
000.060.050.040.070.090.080.080.060.040.050.090.140.170.130.240.110.090.070.040.030.020.020.190.210.160.240.871.120.50.460.260.24
0.81.62.43.63.912.311.714.923.720.5119.79.723.523.622.55.62.912.98.50.60.50.80.90.50.41.84.25.417.537.253.327.525.06
00000000.80.15.23.42.41.300000000000029.78.36.40000048.32
0.10.20.50.90.60.50.50.60.5000000004947.53122.915.38.27.43.4000000000
0.10.20000004341.644.941.9148.5138.1127.4146.883.1021.812.358.355.957.755.356.9230.5248.1251.3230.5606.3561.2352.6366.9
0000000000000000003.40.70.712.212.212.212.212.272.28686.695.2189.7181.2105.7103.37
0.20.110.20.67.84.57.110.610.69.59.927.49.713.212.41.911.511.731.62.22.13.31.60.2189.1125.689.3472828.637.213.36.14
1.22.13.94.75.120.616.723.477.977.968.863.9186.9171.3164.2181.790.663.477.573.638.788.480.479.871.6288.3438.4434390.3371.2861.8832.9499.1549.79
00.010.060.050.050.090.10.110.160.130.110.120.280.310.330.310.330.170.170.140.080.120.10.10.260.50.60.671.261.491.361.30.760.79
                                                                   
0000000000.10.10.10.114.712.412.412.412.412.58.58.48.4000000000000.02
9.620.589.594.1104.7173.5214.9311.7384.7448.8490.5529.4693.2712.9720721891.4651711.2726.8729.3732.7751.5718680.7661.9769.7798.2791.1367.3318.4373147.6198.7
-9.3-15.6-29.6-49-76.1-140.3-177.6-277.7-395.6-470.3-542.7-585.7-618.3-749.5-794.7-831.1-862.8-581.5-679.6-681.6-691.9-682.2-682.8-671.3-659.3-429.5-431.1-400.9-229.2400.1392449.1450.9503.02
00000000.4-0.5-4.1-2-0.70-0.10.20.5-0.500.10.50002.954.92.72.5-1-0.2-0.8-0.9-1-0.82
0000000000000000000000000000000000
0.34.959.945.128.633.237.334.4-11.4-25.5-54.1-56.975-22-62.1-97.240.581.944.254.245.858.968.749.626.4237.3341.3399.8560.9767.2709.6821.2597.5700.91
0.20.31.11.32.33.94.110.712.45.43.85.41218.817.415.412.312.714.620.78.611.15.947.74.12.72.34.22.43.88.45.32.43
0.20.40.91.42.56.74.95.67.28.212.712.216.632.743.959.646.57.121.310.59.98.355.34.95.46.47.219.29.820.419.616.412.25
000.51.622.62.22.64.138.48.74.7105.7152.5157.572.129.732.8211514.36.87.77.910.45.14.932.44.769.313.60.42.1
00000000000000000000010000000000000
0.30.60.81.21.32.42.62.83.24.13.55.42.12.52.92.739.91.51.800017.911.92.4202.9212.9224.526.406.6076.70.01
0.71.33.35.58.115.613.821.726.920.728.431.735.4159.7216.7235.2170.85170.552.233.543.735.628.922.9222.8227.1238.982.216.9100.141.698.816.78
0.61.21.82.312.349.953.951.490.5136.6131.7136.8159.3170.1171.1170.22.20.62.20020.319.43.1196.839.629.618.9609.9639442.3320.700
000000000000000000028.10.42.20.71.12.8000032.964.659.130.631.62
00000000502.98.46.96.77.27.67.3113.480.296.749.438.237.922.22211.23.33.613.57.838.845.85535.837.9
0.61.21.82.312.349.953.951.4140.5139.5140.1143.7166177.3178.7177.5115.680.898.977.538.660.442.326.2210.842.933.232.4617.7710.7552.7434.866.469.52
1.32.55.17.820.465.567.773.1167.4160.2168.5175.4201.4337395.4412.7286.4131.8169.4129.772.1104.177.955.1233.7265.7260.3271.3699.9727.6652.8476.4165.286.3
00.010.070.050.050.10.110.110.160.130.110.120.280.320.330.320.330.210.210.180.120.160.150.10.260.50.60.671.261.491.361.30.760.79
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Ligand Pharmaceuticals provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Ligand Pharmaceuticals's financial health and stability.

Assets

Ligand Pharmaceuticals's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Ligand Pharmaceuticals must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Ligand Pharmaceuticals after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Ligand Pharmaceuticals's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
19891990199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
-2-4-6-14-19-27-64-37-100-117-74-72-43-52-96-45-36-31281-98-1-10901110227-112143629-357-3352
00001146647768141417152142222221111141825515136
0000000000000000000000-13-100-19210442974-19-82011
0000031-412-1-77113704126-82-55-1-18-24-5-20-100-12-16-41-4-10-5265-34
0003882226748151215312-40-39-31981-14885122816716168-7239170939
0000003555444491011910002210111154310
00000000000000000080000000000010323118
-2-3-5-10-10-14-36-33-13-66-59-45-19-26058-138-97-20-33-27-102020416088194-29547813749
00000000-7-5-2-1-2-109-6-3-35-1000000-3-1-4-19-2-10-2-4-8-17-64
-21-1-5-4312871-31-2512-4-124-1419-33196343-242414-251-5-2-112-134-79-42346623130163-11
-21-1-5-4312878-26-2313-2-14-7231198344-232514-251-1-1-108-114-77-4124692363918152
00000000000000000000000000000000000
000101005533631111531423800003070245000532-27-231-164-261-76
60865410193936382214287033609-35-100063-51822-42-450-7515322
6096431916443968821235171327033-327-3-30303-161308-5-7328-485-310-137-276-59
000-1-1-1-30-2-2-2-3-4-52-2-3-3-14-39-1-300-10-19-630-7-10-161-7-311-18-5
000000000000000000-2520000000000000000
1-2349-51681827-29-3-2011201833-2591-81-48-12-12350148-62-78199-47-24-2825-22
-2.4-3.9-5.3-10.4-10.9-14.9-36.7-33.7-20.8-72.1-62.1-46.3-21.9-136.4-6.62.2-27.2-140.3-98.1-21.1-34.3-27.2-1.3-0.416.819.637.641.286.4183.2-31.950.170120-14.68
00000000000000000000000000000000000

Ligand Pharmaceuticals stock margins

The Ligand Pharmaceuticals margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Ligand Pharmaceuticals. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Ligand Pharmaceuticals.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Ligand Pharmaceuticals's sales revenue. A higher gross margin percentage indicates that the Ligand Pharmaceuticals retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Ligand Pharmaceuticals's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Ligand Pharmaceuticals's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Ligand Pharmaceuticals's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Ligand Pharmaceuticals. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Ligand Pharmaceuticals's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Ligand Pharmaceuticals Margin History

Ligand Pharmaceuticals Gross marginLigand Pharmaceuticals Profit marginLigand Pharmaceuticals EBIT marginLigand Pharmaceuticals Profit margin
2030e91.99 %37.5 %0 %
2029e91.99 %39.56 %0 %
2028e91.99 %35 %0 %
2027e91.99 %32.5 %0 %
2026e91.99 %51.68 %60.77 %
2025e91.99 %47.72 %62.78 %
2024e91.99 %15.46 %64.11 %
202391.99 %7.48 %39.72 %
202273.09 %1.53 %-17.02 %
202177.59 %28.47 %20.61 %
202083.69 %4.67 %-1.61 %
201990.52 %-4.74 %523.11 %
201897.46 %65.09 %56.98 %
201796.17 %48.26 %8.93 %
201694.86 %41.19 %-1.47 %
201591.93 %39.36 %319.61 %
201485.89 %32.09 %18.6 %
201388.16 %32.45 %23.27 %
201288.54 %3.82 %-1.59 %
201183.67 %6.33 %32.33 %
2010100 %-41.28 %-44.26 %
2009100 %14.65 %-4.88 %
200891.99 %-92.67 %-359.34 %
200791.99 %-466.67 %2,183.72 %
200691.99 %-1,952.5 %-792.5 %
200591.99 %-427.45 %-356.86 %
200483.68 %-13.74 %-40.32 %

Ligand Pharmaceuticals Stock Sales Revenue, EBIT, Earnings per Share

The Ligand Pharmaceuticals earnings per share therefore indicates how much revenue Ligand Pharmaceuticals has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Ligand Pharmaceuticals earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Ligand Pharmaceuticals's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Ligand Pharmaceuticals’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Ligand Pharmaceuticals's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Ligand Pharmaceuticals Revenue, EBIT and net profit per share

DateLigand Pharmaceuticals Sales per ShareLigand Pharmaceuticals EBIT per shareLigand Pharmaceuticals Earnings per Share
2030e26.85 undefined0 undefined0 undefined
2029e19.79 undefined0 undefined0 undefined
2028e16.22 undefined0 undefined0 undefined
2027e13.19 undefined0 undefined0 undefined
2026e12.37 undefined0 undefined7.52 undefined
2025e10.15 undefined0 undefined6.37 undefined
2024e8.58 undefined0 undefined5.5 undefined
20237.4 undefined0.55 undefined2.94 undefined
202211.61 undefined0.18 undefined-1.98 undefined
202116.11 undefined4.59 undefined3.32 undefined
202011.51 undefined0.54 undefined-0.19 undefined
20196.08 undefined-0.29 undefined31.78 undefined
201810.44 undefined6.79 undefined5.95 undefined
20176 undefined2.9 undefined0.54 undefined
20165.24 undefined2.16 undefined-0.08 undefined
20153.39 undefined1.33 undefined10.84 undefined
20143.01 undefined0.97 undefined0.56 undefined
20132.37 undefined0.77 undefined0.55 undefined
20121.58 undefined0.06 undefined-0.03 undefined
20111.52 undefined0.1 undefined0.49 undefined
20101.2 undefined-0.49 undefined-0.53 undefined
20092.06 undefined0.3 undefined-0.1 undefined
20081.72 undefined-1.59 undefined-6.17 undefined
20070.79 undefined-3.67 undefined17.18 undefined
20060.3 undefined-5.83 undefined-2.37 undefined
20050.83 undefined-3.54 undefined-2.96 undefined
20049.11 undefined-1.25 undefined-3.67 undefined

Ligand Pharmaceuticals business model

Ligand Pharmaceuticals Inc is an American company that has been operating in the biotechnology industry for over 30 years. It was founded in 1987 in San Diego, California and has since built an impressive track record. The business model of Ligand Pharmaceuticals Inc is based on the development and commercialization of innovative drugs and technologies for the pharmaceutical and biotechnology industry. The company is a leading provider of resources for drug discovery and development, including ligand design, synthesis and analysis, tools for drug screening, and technologies for therapy optimization. Ligand Pharmaceuticals Inc is divided into several business segments that focus on different industries and categories of medication. These include oncology, immunology, neurology, metabolic diseases, and rare diseases. One of the key areas of Ligand Pharmaceuticals Inc is oncology, which focuses on the development of cancer drugs. The company currently has several innovative drugs in the pipeline targeting various types of cancer and showing promising results in clinical trials. Another important area of Ligand Pharmaceuticals Inc is immunology, which focuses on the development of drugs for autoimmune diseases. The company has some promising partnerships in this field, including one with Bristol Myers Squibb for the joint development of antibodies against the CTLA-4 receptor. In addition to drug development, Ligand Pharmaceuticals Inc also offers various technologies and tools for drug screening and therapy optimization. These include platforms for antibody and small molecule discovery, as well as technologies for antibody manufacturing and genome editing. Another important aspect of Ligand Pharmaceuticals Inc's business model is its partnership with other pharmaceutical companies. The company heavily relies on collaboration and currently has several strategic partnerships with some of the world's largest pharmaceutical companies. These partnerships allow Ligand to provide its partners with access to its technology and drug candidates, thereby expanding its portfolio. Over the years, Ligand Pharmaceuticals Inc has brought many successful products and technologies to the market. Some of the most well-known and successful products include Kyprolis, a treatment for multiple myeloma, and Promacta, a medication for immune thrombocytopenia. Overall, Ligand Pharmaceuticals Inc has built an impressive track record and is now considered one of the leading providers of resources for drug discovery and development. The company continues to prioritize collaboration and innovation and will undoubtedly bring many more innovative products and technologies to the market in the future. Ligand Pharmaceuticals is one of the most popular companies on Eulerpool.com.

Ligand Pharmaceuticals SWOT Analysis

Strengths

Ligand Pharmaceuticals Inc possesses several strengths that contribute to its success in the pharmaceutical industry. These strengths include:

  • Strong product portfolio: Ligand Pharmaceuticals Inc has a diverse range of high-quality and innovative pharmaceutical products.
  • Strong intellectual property: The company holds numerous patents, providing a competitive advantage and ensuring protection for its products.
  • Partnership network: Ligand Pharmaceuticals Inc has established strategic partnerships with leading pharmaceutical companies, allowing for expanded market reach and increased revenue opportunities.
  • Financial stability: The company has a strong financial standing, with healthy revenues and profitability, enabling it to invest in research and development activities.

Weaknesses

Despite its strengths, Ligand Pharmaceuticals Inc also faces certain weaknesses that can hinder its growth. These weaknesses include:

  • Dependency on key partners: Ligand Pharmaceuticals Inc relies heavily on a few key partners for a significant portion of its revenue, posing a risk if these partnerships were to be disrupted.
  • Relatively small scale: Compared to some larger pharmaceutical companies, Ligand Pharmaceuticals Inc operates on a smaller scale, limiting its resources and potentially hindering its ability to compete in certain areas.
  • Vulnerability to regulatory changes: As a pharmaceutical company, Ligand Pharmaceuticals Inc is subject to constantly evolving regulations and policies, which may impact its operations and profitability.

Opportunities

Ligand Pharmaceuticals Inc can leverage various opportunities to further expand its market presence and drive growth. These opportunities include:

  • Emerging markets: The company can explore untapped markets in developing countries, where demand for pharmaceuticals is increasing.
  • Expanding product offerings: Ligand Pharmaceuticals Inc has the potential to develop new drugs or expand its product line to address unmet medical needs and capture new market segments.
  • Advancements in technology: The company can benefit from advancements in technology, such as personalized medicine and biotechnology, to enhance its product development and improve patient outcomes.

Threats

Ligand Pharmaceuticals Inc operates in a highly competitive and regulated industry, facing several threats that could impact its success. These threats include:

  • Competition: The pharmaceutical industry is characterized by intense competition from both large pharmaceutical companies and emerging biotech firms, increasing the challenge to maintain market share.
  • Stringent regulations: The regulatory landscape for pharmaceutical companies is complex and can restrict market access or increase operational costs through compliance requirements.
  • Patent expiry: Like many pharmaceutical companies, Ligand Pharmaceuticals Inc faces the risk of patent expirations, which can lead to generic competition and erosion of market share.
  • Healthcare reforms: Changes in healthcare policies and reimbursement models can impact the pricing and demand for pharmaceutical products, potentially affecting the company's financial performance.

Ligand Pharmaceuticals Revenue by Segment

  • 3 years

  • 5 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Ligand Pharmaceuticals Revenue by Segment

Segmente2014
Contract-
Captisol-
Royalties-
Contract revenue-
License fees, milestones and other revenues-
Material sales-
CyDex37.36 M USD
Ligand27.17 M USD

Ligand Pharmaceuticals Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Ligand Pharmaceuticals historical P/E ratio, EBIT, and P/S ratio.

Ligand Pharmaceuticals shares outstanding

The number of shares was Ligand Pharmaceuticals in 2023 — This indicates how many shares 17.757 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Ligand Pharmaceuticals earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Ligand Pharmaceuticals's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Ligand Pharmaceuticals’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Ligand Pharmaceuticals's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Ligand Pharmaceuticals Stock splits

In Ligand Pharmaceuticals's history, there have been no stock splits.

Ligand Pharmaceuticals dividend history and estimates

In 2023, Ligand Pharmaceuticals paid a dividend amounting to 0 USD. Dividend means that Ligand Pharmaceuticals distributes a portion of its profits to its owners.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details

Dividend

ⓘ

Dividend Overview

The dividend per year chart for Ligand Pharmaceuticals provides a comprehensive view of the annual dividends distributed to shareholders. Analyze the trend to understand the consistency and growth in dividend payouts over the years.

Interpretation and Use

A consistent or increasing trend in dividends can indicate the company's profitability and financial health. Investors can use this data to identify Ligand Pharmaceuticals’s potential for long-term investment and income generation through dividends.

Investment Strategy

Incorporate the dividend data in evaluating Ligand Pharmaceuticals's overall performance. A thorough analysis, considering other financial aspects, will help in making informed investment decisions for optimal capital growth and income generation.

Ligand Pharmaceuticals Dividend History

DateLigand Pharmaceuticals Dividend
200715 undefined

Ligand Pharmaceuticals dividend payout ratio

In 2023, Ligand Pharmaceuticals had a payout ratio of 87.36%. The payout ratio indicates the percentage of the company's profits that Ligand Pharmaceuticals distributes as dividends.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Payout ratio
Details

Payout ratio

ⓘ

What is Yearly Payout Ratio?

The yearly payout ratio for Ligand Pharmaceuticals represents the proportion of earnings paid out as dividends to shareholders. It is an indicator of the company's financial health and stability, illustrating how much profit is being returned to investors versus being reinvested back into the company.

How to Interpret the Data

A lower payout ratio for Ligand Pharmaceuticals could mean that the company is reinvesting more into its growth, whereas a higher ratio indicates more earnings are being distributed as dividends. Investors seeking regular income might prefer companies with a higher payout ratio, while those looking for growth may opt for companies with a lower ratio.

Using the Data for Investments

Evaluate Ligand Pharmaceuticals's payout ratio in conjunction with other financial metrics and performance indicators. A sustainable payout ratio, coupled with strong financial health, can indicate a reliable dividend payout. However, a very high ratio might suggest the company is not sufficiently reinvesting in its future growth.

Ligand Pharmaceuticals Payout Ratio History

DateLigand Pharmaceuticals Payout ratio
2030e87.36 %
2029e87.36 %
2028e87.36 %
2027e87.36 %
2026e87.36 %
2025e87.36 %
2024e87.36 %
202387.36 %
202287.36 %
202187.36 %
202087.36 %
201987.36 %
201887.36 %
201787.36 %
201687.36 %
201587.36 %
201487.36 %
201387.36 %
201287.36 %
201187.36 %
201087.36 %
200987.36 %
200887.36 %
200787.36 %
200687.36 %
200587.36 %
200487.36 %
Unfortunately, there are currently no price targets and forecasts available for Ligand Pharmaceuticals.

Ligand Pharmaceuticals latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/20241.08 1.4  (29.98 %)2024 Q2
3/31/20240.79 1.2  (50.98 %)2024 Q1
12/31/20230.67 1.38  (104.75 %)2023 Q4
9/30/20230.62 1.02  (63.93 %)2023 Q3
6/30/20230.65 1.42  (117.62 %)2023 Q2
3/31/20230.91 2.28  (150.03 %)2023 Q1
12/31/20221.22 1.36  (11.74 %)2022 Q4
9/30/20220.44 1.31  (197.46 %)2022 Q3
6/30/20220.44 1.03  (134.84 %)2022 Q2
3/31/20220.67 0.58  (-13.41 %)2022 Q1
1
2
3
4
5
...
11

Eulerpool ESG Scorecard© for the Ligand Pharmaceuticals stock

Eulerpool World ESG Rating (EESG©)

30/ 100

🌱 Environment

19

👫 Social

19

🏛️ Governance

52

Environment

Scope 1 - Direct Emissions
—
Scope 2 - Indirect emissions from purchased energy
—
Scope 3 - Indirect emissions within the value chain
—
Total CO₂ emissions
—
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
✅
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
❌
Environmentally friendly packaging
❌
Hazardous substances
❌
Fuel consumption and efficiency
❌
Water consumption and efficiency
❌

Social

Percentage of female employees—
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept❌
Privacy concept—
Occupational health and safety✅
Catholic✅

Governance (Corporate Governance)

Environmental reporting❌
Stakeholder Engagement❌
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Ligand Pharmaceuticals list of shareholders

%
Name
Stocks
Change
Date
7.35169 % Janus Henderson Investors1,343,1541,28112/31/2023
5.40424 % Macquarie Investment Management987,354-4,46412/31/2023
3.65782 % State Street Global Advisors (US)668,28445,02912/31/2023
3.61958 % Dimensional Fund Advisors, L.P.661,29846,90612/31/2023
3.60938 % Stephens Investment Management Group, LLC659,434191,87012/31/2023
2.34292 % St. Denis J. Villere & Company, LLC428,051-10,11012/31/2023
2.28623 % Higgins (John L)417,69571,4754/14/2023
2.02964 % Geode Capital Management, L.L.C.370,81518,19412/31/2023
14.93572 % BlackRock Institutional Trust Company, N.A.2,728,756143,36612/31/2023
10.25061 % The Vanguard Group, Inc.1,872,78624,65312/31/2023
1
2
3
4
5
...
10

Ligand Pharmaceuticals Executives and Management Board

Mr. Matthew Korenberg48
Ligand Pharmaceuticals President, Chief Operating Officer
Compensation 6.54 M
Mr. Todd Davis62
Ligand Pharmaceuticals Chief Executive Officer, Director (since 2007)
Compensation 5.2 M
Mr. Octavio Espinoza52
Ligand Pharmaceuticals Chief Financial Officer
Compensation 3.27 M
Mr. Andrew Reardon48
Ligand Pharmaceuticals Chief Legal Officer
Compensation 3.01 M
Dr. John Kozarich73
Ligand Pharmaceuticals Non-Executive Independent Chairman of the Board
Compensation 586,596
1
2
3

Most common questions regarding Ligand Pharmaceuticals

What values and corporate philosophy does Ligand Pharmaceuticals represent?

Ligand Pharmaceuticals Inc represents values of innovation, collaboration, and integrity in the pharmaceutical industry. The company is committed to discovering and developing breakthrough medicines that address unmet medical needs. With a strong focus on research and development, Ligand strives to develop novel therapies that improve patient outcomes. The company's corporate philosophy centers around teamwork and partnerships, as it collaborates with leading pharmaceutical companies to bring innovative therapies to market. Through its cutting-edge technology platforms and strategic acquisitions, Ligand Pharmaceuticals Inc continues to make significant contributions to the advancement of modern medicine.

In which countries and regions is Ligand Pharmaceuticals primarily present?

Ligand Pharmaceuticals Inc is primarily present in the United States and holds a strong presence in other regions such as Europe and Asia. As a leading biopharmaceutical company, Ligand has strategically established its global footprint to capitalize on market opportunities and expand its reach. With a commitment to innovation and collaboration, Ligand aims to enhance patient care and deliver transformative therapies worldwide.

What significant milestones has the company Ligand Pharmaceuticals achieved?

Ligand Pharmaceuticals Inc has achieved several significant milestones throughout its history. Some notable accomplishments include the successful development and commercialization of various novel therapeutics across multiple therapeutic areas. The company has also formed strategic collaborations with renowned pharmaceutical companies, which have helped expand its product portfolio and global reach. Ligand Pharmaceuticals Inc has received multiple regulatory approvals for its innovative drugs, demonstrating its commitment to delivering high-quality and effective treatments. The company's successful track record in research and development, coupled with its strong partnerships, has positioned Ligand Pharmaceuticals Inc as a leading player in the pharmaceutical industry.

What is the history and background of the company Ligand Pharmaceuticals?

Ligand Pharmaceuticals Inc is a renowned biopharmaceutical company that specializes in developing and acquiring technologies for the discovery and development of innovative drugs. Established in 1987, the company has a rich history of pioneering advancements in drug discovery. Ligand Pharmaceuticals Inc operates on a unique business model, utilizing its comprehensive proprietary libraries of drug candidates, which are made available to partners for licensing. This approach has facilitated numerous successful partnerships and collaborations, leading to the approval and commercialization of multiple life-changing therapies. Ligand Pharmaceuticals Inc continues to demonstrate its commitment to advancing medicine through strategic collaborations, research, and development efforts.

Who are the main competitors of Ligand Pharmaceuticals in the market?

The main competitors of Ligand Pharmaceuticals Inc in the market are Amgen Inc., Eli Lilly and Company, and Pfizer Inc.

In which industries is Ligand Pharmaceuticals primarily active?

Ligand Pharmaceuticals Inc is primarily active in the pharmaceutical industry.

What is the business model of Ligand Pharmaceuticals?

Ligand Pharmaceuticals Inc's business model focuses on developing and licensing innovative therapies and technologies for the biopharmaceutical industry. As a leading drug discovery and development company, Ligand partners with pharmaceutical and biotechnology companies to provide access to its broad portfolio of intellectual property, expertise, and research tools. By leveraging their unique Captisol® technology, Ligand is able to enhance the solubility and efficacy of active pharmaceutical ingredients, enabling the development of novel therapies. This business model allows Ligand to generate significant revenue through strategic collaborations and royalty-bearing partnerships while minimizing the risk associated with drug development.

What is the P/E ratio of Ligand Pharmaceuticals 2024?

The Ligand Pharmaceuticals P/E ratio is 18.21.

What is the P/S ratio of Ligand Pharmaceuticals 2024?

The Ligand Pharmaceuticals P/S ratio is 11.68.

What is the AlleAktien quality score of Ligand Pharmaceuticals?

The AlleAktien quality score for Ligand Pharmaceuticals is 3/10.

What is the revenue of Ligand Pharmaceuticals 2024?

The expected Ligand Pharmaceuticals revenue is 156.78 M USD.

How high is the profit of Ligand Pharmaceuticals 2024?

The expected Ligand Pharmaceuticals profit is 100.5 M USD.

What is the business model of Ligand Pharmaceuticals

Ligand Pharmaceuticals Inc. is a biopharmaceutical company focused on researching and developing novel medications. The company's business model is based on identifying, developing, and marketing unique therapeutics specialized in various disease areas. The company operates in three main business segments: Captisol Platform Technology, OmniAb Antibody Research, and Partnered Programs. The Captisol Platform Technology is a patented technology for the production of drugs that helps improve drug solubility and bioavailability. This technology is also used for the production of generics to make them patent-protected and more economically viable. The second segment is OmniAb Antibody Research. This involves an innovative strategy for developing antibody-based therapeutics that can be used for the treatment of cancer, inflammatory, and infectious diseases. This research involves the identification of antibodies specific to target molecules, thus providing effective therapeutics. The third segment, Partnered Programs, focuses on collaborations with other companies. It aims to build a comprehensive network of biotechnology and pharmaceutical companies to jointly develop and market new therapeutics. Ligand offers its partners access to its patented technologies and expertise in the development of new therapeutics. One of Ligand's key products is the orally administered hormone therapy Lasofoxifene, used for the treatment of osteoporosis in postmenopausal women. Additionally, Ligand also holds the license for the distribution of Promacta, a medication developed in collaboration with GlaxoSmithKline for the treatment of thrombocytopenia. Overall, Ligand Pharmaceuticals Inc. highly values partnerships to enhance its innovation and success in the industry. The company relies on its ability to develop innovative technologies and build connections with customers and partners to expand its business. With its patented technologies and expertise in drug research and development, Ligand strives to improve the lives of patients and enhance healthcare overall.

What is the Ligand Pharmaceuticals dividend?

Ligand Pharmaceuticals pays a dividend of 0 USD distributed over payouts per year.

How often does Ligand Pharmaceuticals pay dividends?

The dividend cannot currently be calculated for Ligand Pharmaceuticals or the company does not pay out a dividend.

What is the Ligand Pharmaceuticals ISIN?

The ISIN of Ligand Pharmaceuticals is US53220K5048.

What is the Ligand Pharmaceuticals WKN?

The WKN of Ligand Pharmaceuticals is A1C9RN.

What is the Ligand Pharmaceuticals ticker?

The ticker of Ligand Pharmaceuticals is LGND.

How much dividend does Ligand Pharmaceuticals pay?

Over the past 12 months, Ligand Pharmaceuticals paid a dividend of 15 USD . This corresponds to a dividend yield of about 14.55 %. For the coming 12 months, Ligand Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Ligand Pharmaceuticals?

The current dividend yield of Ligand Pharmaceuticals is 14.55 %.

When does Ligand Pharmaceuticals pay dividends?

Ligand Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Ligand Pharmaceuticals?

Ligand Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Ligand Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Ligand Pharmaceuticals located?

Ligand Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Ligand Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Ligand Pharmaceuticals from 4/19/2007 amounting to 2.5 USD, you needed to have the stock in your portfolio before the ex-date on 4/3/2007.

When did Ligand Pharmaceuticals pay the last dividend?

The last dividend was paid out on 4/19/2007.

What was the dividend of Ligand Pharmaceuticals in the year 2023?

In the year 2023, Ligand Pharmaceuticals distributed 0 USD as dividends.

In which currency does Ligand Pharmaceuticals pay out the dividend?

The dividends of Ligand Pharmaceuticals are distributed in USD.

All fundamentals about Ligand Pharmaceuticals

Our stock analysis for Ligand Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Ligand Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.